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A novel pyranoside mimetic compound, DMBO (2-(2,6-diﬂuorophenyl)-5-(4-methoxy-
phenyl)-1-oxa-3-azaspiro[5.5]undecane), was designed and synthesized. The sugar mim-
icking behavior of DMBO was addressed by its ability to bind several growth factors/
cytokines such as vascular endothelial growth factor (VEGF), heparin-binding epidermal
growth factor-like growth factor (HB-EGF), and tumor necrosis factor (TNF)-a as demon-
strated by the recently developed surface plasmon resonance assay. DMBO exhibited
strong anti-proliferation activity in vitro against tumor cells including a highly metastatic
murine osteosarcoma cell line LM8G7 that secretes VEGF as well as two human ovarian cell
lines, OVSAHO and SKOV-3, which secrete TNF-a and HB-EGF respectively. Furthermore,
DMBO inhibited the metastatic activity to the mouse liver of LM8G7 cells injected from
a lateral tail vein, and affected the heparan-degrading activity of LM8G7 cells. Here, we
report that DMBO acts as a human heparanase inhibitor in vitro possibly as a substrate
mimetic. DMBO also inhibited the migration and invasion of LM8G7 cells and angiogenic
events such as endothelial cell proliferation, migration and capillary tube-like formation
in vitro. More prominently, the administration of DMBO with heparin resulted in synergis-
tic anti-tumor effects in mouse model of osteosarcoma. These preclinical data shows the
potential anti-cancer effects of DMBO.
 2010 Elsevier Ireland Ltd. All rights reserved.and Ltd. All rights reserved.
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JSPS.1. Introduction
Synthetic heterocyclic compounds have been used
extensively for drug development and the treatment of dis-
eases including cancer [1]. Among them, oxazines are well
known for their potential biological effects, for example, the
inactivation of chymotrypsin by 5-butyl-3H-l,3-oxazine-
2,6-dione [2]. In addition, 5-b-D-ribofuranosyl-l,3-oxazin-
2,4-dione, a C-ribonucleoside antibiotic (minimycin), is
used as an anti-tumor agent [3] and 5-methyl-3H-1,3-oxa-
zine-2,6-dione is used as a suicide inactivator of serine
232 Basappa et al. / Cancer Letters 297 (2010) 231–243proteases [4]. In the search for an effective therapeutic
agent for cancer, which targets multiple pathways, we de-
signed and synthesized a novel six-membered oxazine
compound, DMBO (2-(2,6-diﬂuorophenyl)-4a,5,6,7,8,8a-
hexahydro-4a-(4-methoxyphenyl)-4H-benzo[e][1,3]oxa-
zine), a class of sugar mimetic, in which the ring carbon has
been replaced by a nitrogen atom. The oxazine nucleus of
the DMBO is appeared to mimic the pyranoside ring struc-
ture, which is the monosaccharide back bone of the sugar
residues in the heparan sulfate (HS).
HS on cell surfaces modulates signal transduction to
tumor cells by interacting with various growth factors such
as ﬁbroblast growth factor-2 [5], vascular epidermal
growth factor (VEGF) [6], and heparin-binding epidermal
growth factor-like growth factor (HB-EGF) [7]. Cell-surface
and extracellular matrix HS plays a major role in tumor
metastasis, and acts as a storage shed for various proteins
[8]. Heparanase, an endo-b-D-glucuronidase family mem-
ber, promotes tumor cell invasion by degrading HS in the
extracellular matrix [9,10]. Heparanase promotes cell pro-
liferation, metastasis and angiogenesis by releasing growth
factors such as ﬁbroblast growth factor-2 and VEGF from
HS [11,12]. Several studies have shown that HS mimetics
act as anti-tumor agents. For example, anti-tumor and
anti-heparanase activities of a non-sugar-based HS
mimetic compound KI-105 have been reported [13].
In addition to the matrix components and matrix-
degrading enzymes, malignant cells produce a variety of
soluble factors such as VEGF, HB-EGF, and tumor necrosis
factor-a (TNF-a), which play a major role in tumor pro-
gression. Heparin-binding growth factors like ﬁbroblast
growth factor-2, VEGF and HB-EGF have been implicated
in the metastatic process [14]. VEGF plays a major role in
both vasculogenesis and angiogenesis by triggering a tyro-
sine kinase pathway [15]. Some members of the VEGF fam-
ily stimulate cellular responses by binding to cell-surface
heparan sulfate proteoglycans as co-receptors [16]. There-
fore, effective VEGF antagonists or the VEGF receptor ago-
nists that mimic HS may be good tools to inhibit VEGF
production. HB-EGF activates at least three signal trans-
duction pathways, which are involved in proliferation,
the secretion of VEGF, and the stimulation of chemotaxis
in cancer cells [17]. The expression of ligands for the EGF
receptor, such as transforming growth factor-a is also of-
ten increased in gliomas, resulting in an autocrine loop
that contributes to the growth autonomy of glioma cells
[18]. Importantly, HB-EGF and EGF act downstream by
binding to EGF receptor on the cell surface with high afﬁn-
ity [19]. Therefore, it is reasonable to expect either inhibi-
tion of the expression of HB-EGF or blocking of the EGF
receptor pathway to have therapeutic value in the treat-
ment of a variety of cancers. This notion is consistent with
the ﬁnding that neutralizing antibodies against HB-EGF
blocked the transactivation of EGF receptor and inhibited
the tumor growth in mice [20]. Increasing evidence shows
that TNF-a acts as a key mediator for local inﬂammation
and also in the development of cancer, suggesting that
anti-TNF-a therapy might be effective against pancreatic
tumor growth and metastasis [21].
DMBO mimics the pyranosidic ring structure of HS.
Here, we demonstrate DMBO’s ability to bind variousgrowth factors/cytokines such as VEGF, HB-EGF, and TNF-
a and also presented the anti-tumor activity of DMBO with
heparin synergistically.2. Materials and methods
2.1. Synthesis of DMBO
Equimolar 2,6-diﬂuoro benzaldehyde (0.44 g) was
added to a solution of 1-[2-amino-1-(4-methoxy-phenyl)-
ethyl]-cyclohexanol monoacetate (1.0 g, 3.13 mmol) in
5.0 mL of methanol in the presence of anhydrous K2CO3
(1.3 g, 10 mmol) and the reaction mixture was stirred at
room temperature for 10–12 h to obtain DMBO. Dry
weight: 0.85 g, yield: 85%, m.p. 102 C. The analytical grade
compound was obtained by recrystallization using metha-
nol as a solvent (6 mL). The product was conﬁrmed by IR,
1H NMR and elemental analysis. 1H NMR (400 MHz,
CDCl3): dH 0.75–0.93 (t, 2H, cyclohexyl); 1.1–1.6 (m, 6H,
cyclohexyl); 2.48–2.65 (t, 2H, cyclohexyl); 3.32 (s, 1H, –
NH–); 3.47–58 (t, 2H, N–CH2–); 3.64–3.73 (s, 3H, O-CH3);
3.78–3.82 (t, 1H, –CH–Bz–O–CH3); 5.67–5.69 (br d, 1H, –
CH–Bz); 6.75–6.90 (d, J = 16 Hz, 2H, Ar–H); 7.05–7.18 (d,
J = 8 Hz, 4H, Ar–H); 7.3–7.5 (m, 1H, Ar–H). Anal.
(C22H25F2NO2) C, H, N. Molecular weight: 373.4 Da. The
melting points were determined on a SELACO-650 hot
stage apparatus and are uncorrected. 1H NMR were re-
corded on a Shimadzu AMX 400 spectrometer by using
CDCl3 as solvent and TMS as an internal standard (Chemi-
cal shift in ppm). Elemental analyses were obtained on a
vario-EL instrument and were within ±0.4% of calculated
values.
2.2. X-ray crystallographic study of DMBO
A single crystal of DMBO of good quality was obtained
by slow evaporation using methanol as a solvent at room
temperature. The crystal (0.25  0.2  0.2 mm) was
selected after optical microscopic examination. X-ray dif-
fraction intensity was measured by x scans using a DIPlab-
o 32001 diffractometer attached to a CCD area detector and
a graphite monochromator for Mo Ka radiation (50 kV,
40 mA). A hemisphere of reciprocal space was collected
using the SMART software with the 2h setting of the detec-
tor at 28. Data reduction was performed using the SAINT
program (Siemens). The phase problem was solved by di-
rect methods, and the non-hydrogen atoms were reﬁned
anisotropically by means of the full matrix least-squares
procedure using the SHELXL97 program (Siemens). All
the hydrogen atoms were located using the difference Fou-
rier method. The absolute structure of DMBO is shown
(Fig. 1C). Crystallographic data for the structural analysis
have been deposited at the Cambridge Crystallographic
Data Centre, CCDC-272761 for DMBO.
2.3. Biological materials
Nine-week-old female C3H/HeN mice and 10-week-
old male C57BL/6 mice were obtained from Japan SLC
(Hamamatsu, Japan) and kept in standard housing. All
Fig. 1. Synthesis and crystal structure of a novel HS mimetic DMBO. (A) The comparison of the pyranose ring of the HS disaccharide unit and its mimetic
oxazine ring of DMBO. (B) Schematic diagram for the synthesis of DMBO. (C) X-ray crystal structure of DMBO showing the Oak Ridge Thermal Ellipsoid Plot
view. The color coding of the atoms is as follows: black, carbon; dark blue, nitrogen; red, oxygen; light green, ﬂuorine; small black circles, hydrogen. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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approved by the local animal care committee of Hokkaido
University. LM8G7, a highly metastatic murine osteosar-
coma cell line with the potential to form tumor nodules
in the liver, was cloned from LM8G5 cells [22] as described
[23,24] and cultured in Dulbecco’s Modiﬁed Eagle’s Med-
ium (DMEM) supplemented with 10% (v/v) fetal bovine
serum (FBS) (Thermo Trace, Melbourne, Australia), strepto-
mycin (100 lg/mL), penicillin (100 units/mL), 100 non-
essential amino acids, b-mercaptoethanol (50 lM), 100
sodium pyruvate, and L-glutamine (2 mM) at 37 C in a
humidiﬁed 5% CO2 atmosphere. The cells were harvested
after incubation with 0.1% trypsin/1 mM EDTA in PBS for
5 min at 37 C followed by gentle ﬂushing with a pipette,
and subcultured thrice a week. Human ovarian cancer cells
(OVSAHO and SKOV-3) and mouse vascular endothelial
cells (UV$2) were purchased from RIKEN Cell Bank, Japan.
The OVSAHO cells were cultured in RPMI medium supple-
mented with 10% (v/v) FBS, L-glutamine (2 mM), and NaH-
CO3 (10%). The SKOV-3 cells were cultured in McCoy’s 5Amedium supplemented with 10% (v/v) FBS and L-glutamine
(2 mM). The UV$2 cells were maintained in DMEM supple-
mented with 10% (v/v) FBS. Bovine serum albumin (BSA),
cisplatin, suramin, recombinant human HB-EGF (rh-HB-
EGF), rh-HGF, rh-midkine, rh-TNF-a, rh-VEGF165, and rh-
pleotrophin were purchased from Wako Pure Chemicals
Co. (Osaka, Japan). Mifepristone and lipopolysaccharide
(LPS) were from Sigma (St. Louis, MO). All other chemicals
and reagents used were of the highest commercial grade
available.
2.4. Surface plasmon resonance (SPR) assay
To introduce DMBO and other small molecules onto a
gold surface for SPR measurements, photo-afﬁnity-linker-
coated gold substrates were prepared. Brieﬂy, a gold-
coated glass chip (TOYOBO, Osaka, Japan) was immersed
in a 0.5 mL ethanol solution, which contained 0.1 mM of
the photo-afﬁnity linker and 0.9 mM of a dummy linker
for 12 h. The chip was rinsed successively with ethanol,
234 Basappa et al. / Cancer Letters 297 (2010) 231–243water and ethanol, and then dried to obtain a photo-reac-
tive chip. The oxazines solution (10 mM in dimethyl sulf-
oxide (DMSO)) was spotted on the chip using an
automated spotter (TOYOBO). The chip was dried in vacuo,
and then irradiated at 365 nm under a UV transmission ﬁl-
ter (Sigma-Koki, Japan) with a CL-1000L ultraviolet cross-
linker (UVP Inc., CA). The chip was washed with DMSO
for 12 h and then rinsed with ethanol. The oxazines-immo-
bilized gold substrate was set into an SPR imaging instru-
ment (TOYOBO), and each growth factor (50 lg/mL) in
the running buffer (10 mM HEPES, 150 mM NaCl, pH 7.4)
was injected onto the array surface at 0.1 mL/min and
incubated for 10 min. All SPR experiments were performed
at 30 C. The interaction between the oxazines and the
growth factors/cytokines such as VEGF, HB-EGF, TNF-a,
FGF-2, midkine, pleotrophin and BSA were carried out
using the SPR imaging instrument. The SPR image and sig-
nal data were collected with an SPR analysis program
(TOYOBO). The SPR difference image was constructed by
using the Scion Image program (Scion, MD).
2.5. Real-time proliferation assay
The cell proliferation assay was done using the RT-
CES™ system (ACEA Biosciences, San Diego, CA). LM8G7
(5  103 cells/well) or OVSAHO (15  103 cells/well) cells
were seeded in ACEA’s 96X e-plate™ in a ﬁnal volume of
150 lL [25]. Approximately 24 h after seeding, when in a
log growth phase, the cells were incubated with 150 lL
of DMEM containing various concentrations of DMBO
(10–80 lM) or DMEM containing DMSO as a control. The
effects of DMBO on the proliferation of LM8G7 or OVSAHO
cells were monitored dynamically every 10 min. A cell in-
dex (quantitative measurement of cell proliferation) was
plotted against time. The IC50 values were calculated from
concentration–response curves by a non-linear regression
analysis using the GraphPad Prism(GraphPad Prism Soft-
ware Inc., San Diego, CA).
2.6. In vitro cell proliferation assay
SKOV-3 or UV$2 cells were seeded at a density of
10  103 cells/well in a 96-well plate and incubated over-
night at 37 C. The SKOV-3 or UV$2 cells were treated with
DMBO for an additional 48 h or 72 h respectively. The ﬁnal
concentrations of DMBO used were (1, 17 or 195 lM) for
SKOV-3 cells. Mifepristone (155 lM) or cisplatin (10 lM)
was used as a positive control. The UV$2 cells were treated
with DMBO (1–59 lM) in the presence of VEGF (2 ng/mL)
or DMBO (2–96 lM) alone in the absence of VEGF. In other
instances, to investigate the speciﬁc effects of DMBO on
VEGF-mediated cell proliferation, DMBO (50 lM) or hepa-
rin (100 lg/mL) were incubated with LM8G7 cells along
with various concentration of exogenous VEGF (0–6 ng/
mL) for 48 h and used for the experiment. In addition,
to investigate the possible synergistic or additive effects
of DMBO and heparin on the proliferation of LM8G7 cells,
DMBO (25 or 50 lM) alone and heparin (25 or 50 lg/mL)
alone or in combination of DMBO (25 or 50 lM) with hep-
arin (25 or 50 lg/mL) was tested. The DMSO solution of
DMBO was diluted with DMEM (150 lL) to yield a ﬁnalconcentration of 1–195 lM (ﬁnal concentration of DMSO,
<0.1%). The viability of control cells and cells treated with
DMBO was measured using the Tetracolor One cell prolif-
eration assay kit (Seikagaku Co., Tokyo, Japan). Absorbance
at 450 nm was monitored to calculate the viability of the
cells in percentage terms.
2.7. Liver metastasis assay
C3H/HeN mice were intravenously injected with
1  106 LM8G7 cells in 200 lL of serum-free DMEM via
the lateral tail vein on day 0. Some mice received an intra-
venous injection of DMBO (0.25, 0.5, 1.0 or 1.5 mg/kg body
weight) suspended in 200 lL of serum-free DMEM, on day
3, 5 and 10 after the tumor cell injection. After 4 weeks, the
mice were sacriﬁced, the number of liver nodules was
counted macroscopically, and liver weight was measured
in the control and DMBO-treated animals. Heparin (2.5 or
5.0 mg/kg body weight) alone was used, as a positive con-
trol. The possible synergistic or additive effects of DMBO
and Heparin were investigated by subsequent administra-
tion of DMBO (0.25 or 0.5 mg/kg body weight) and heparin
(2.5 or 5.0 mg/kg body weight) as described above.
2.8. Heparanase activity assay
Human heparanase activity in vitro was determined
using ﬂuorescein isothiocyanate (FITC)-HS as the substrate,
as described previously [26]. The reactions were carried
out in the presence or absence of DMBO (28, 58, 78, 100
or 118 lM) in 100 lL of 0.1 M sodium acetate buffer, pH
4.2, containing 1 lg of FITC-HS, at 37 C for 3 h and termi-
nated the reaction by heating at 100 C for 5 min. The reac-
tion mixture was centrifuged at 15,000 rpm for 5 min to
precipitate the insoluble material. The products of FITC-
HS yielded by this reaction were analyzed by gel-perme-
ation chromatography. Brieﬂy, a 20-lL aliquot of the
supernatant was injected into a TSKgel G3000SWXL
column (Tosoh Biosciences, Montgomeryville, PA) equili-
brated with column buffer (25 mM Tris–HCl, 150 mMNaCl,
pH 7.5) at a ﬂow rate of 1 mL/min. The activity was deter-
mined from HPLC chromatograms by measuring a forward
half area of the peak of the intact FITC-HS. The decrease of
the peak area observed following heparanase treatment
was measured by using an integrator, and the amount of
the degraded FITC-HS was calculated from the decrease
in ﬂuorescence intensity. One unit was deﬁned as the
quantity of the enzyme that degraded 10 ng of FITC-HS/
min. Suramin (50 lM), a heparanase antagonist was used
a positive control.
2.9. In vitro heparan-degrading assay
LM8G7 (1  106) cells were seeded into a 6-well plate
and incubated overnight. After 24 h, the cells were incu-
bated with DMBO at concentrations of 55, 104, and
206 lM in triplicate. To determine the effect of DMBO on
the heparan-degrading activity of LM8G7, the cells were
further incubated for 48 h at 37 C. The cells were collected
by centrifugation, and a whole-cell lysate was prepared as
reported [27]. Protein concentrations of the samples were
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(Thermo Fisher Scientiﬁc Inc., Rockford, IL), and adjusted
to 0.1 mg/mL. The heparan-degrading activity in DMBO-
treated/untreated cell lysates was measured using a Hepa-
ran Degrading Enzyme Kit (Takara, Ootsu, Japan).
2.10. Cell migration and invasion assays in vitro
The migration or invasion of LM8G7 cells was assessed
using BD BioCoat™ chamber with or without Matrigel (BD
Biosciences) in vitro. Brieﬂy, single cell suspensions of
LM8G7 (2  105 cells/mL) were prepared by detaching
and resuspending the cells in DMEM. Before the cells were
added, the chambers were rehydrated for 2 h in an incuba-
tor at 37 C. The lower chambers were ﬁlled with DMEM
containing 10% FBS. After the addition of the cells with or
without DMBO (0.5–5 lM) to the upper chamber, the
chambers were incubated for a further 8 h at 37 C. The
cells that had not migrated or invaded were removed from
the upper surface of the membrane by scrubbing. The cells
that had migrated or invaded through and remained bound
to the underside of the ﬁlter were ﬁxed, stained with a
Diff-Quick solution, and counted in ﬁve random ﬁelds per
ﬁlter. Images of migrated cells were captured by a phase
contrast microscope (Olympus, IX70, Japan). The number
of migrated or invaded cells in the presence or absence of
DMBO was counted.
2.11. Migration of UV$2 cells in a wound closure model
UV$2 cells were seeded in a 6-well plate and allowed to
grow to complete conﬂuence. Subsequently, a plastic pip-
ette tip was used to scratch the cell monolayer to create
a cleared area, and the wounded UV$2 cell layer was
washed with a fresh medium to remove loose cells, andFig. 2. Interaction between DMBO and growth factors/cytokines. Overview of the
linker-coated gold substrates. Interactions were detected between DMBO and the
SPR signal strength observed by DMBO and VEGF (B), TNF-a (C), or HB-EGF (D).photographed using CKX41 Olympus microscope (Olym-
pus, Japan) equipped with 10 objective lenses. The cells
were incubated with or without DMBO (0.5 or 1 lM) along
with 2 ng/mL VEGF, and the inhibition of the wound heal-
ing by DMBO was photographed after 8 h incubation.
2.12. In vitro angiogenesis assay
ECMatrix™ (Chemicon, CA) was added to a 96-well plate
in a ﬁnal volume of 100 lL and allowed to solidify at 37 C
for 30 min. Single cell suspensions of UV$2 cells (100 lL)
were seeded at a density of 4  105 cells/mL to the ECMa-
trix™-coated wells with or without the indicated concen-
trations of DMBO (0.5 or 1 lM) along with 2 ng/mL VEGF.
After 8 h of culture, the reorganization of the sub-conﬂuent
monolayer of UV$2 cells in 3-dimensional ECMatrix™ was
monitored and photographed under an Olympus FX380
microscope attached to a 3CCD camera. The number of
tubes present in each well was counted and averaged.
2.13. Statistical analysis
The statistical analysis was done using a software
Origin 8 (OriginLab). The Mann–Whitney U test was used
to determine P-values.
3. Results and discussion
Heparin and most of the HS mimetics that act to enhance the inhibi-
tion of inﬂammation and tumor metastasis are sulfated oligosaccharides
(e.g., heparin derivatives, laminarin sulfate, and chitin derivatives)
[28–30]. Low molecular weight HS mimetics which perform multiple bio-
logical functions in vivo and in vitro with high speciﬁcity are rare. Among
HS mimetics, PI-88 (phospho mannopentaose) has been reported as an
anti-tumor agent, which signiﬁcantly inhibits tumor growth, metastasis,
and angiogenesis [31]. An HS mimicking a pseudodisaccharide has been
reported as an inhibitor of heparanase [32]. All these compounds have aSPR analysis (A). DMBO (10 mM) was immobilized on the photo-afﬁnity-
growth factors/cytokines in solution by SPR imaging; B–D, the maximum
P < 0.05 versus control. P < 0.01 versus control. Mann–Whitney U test.
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synthesize a novel non-sugar-based compound, DMBO, which appears
to mimic the functional groups and pyranoside ring structure present in
HS in the form of monosaccharide backbone (Fig. 1A).
3.1. Synthesis of DMBO
The DMBO was prepared by the cyclization of 1-[2-amino-1-(4-meth-
oxy-phenyl)-ethyl]-cyclohexanol monoacetate [33,34] with 2,6-diﬂuoro
benzaldehyde in the presence of potassium carbonate (Fig. 1B). Further,
we obtained DMBO in single crystalline form (Fig. 1C).Fig. 3. Effects of DMBO on the proliferation of cancer cells. (A) Real-time monitor
were seeded in ACEA’s 96X e-plate™ at a density of 5  103 cells per well, and co
DMBO (10–80 lM) was added. The cell index is plotted against the time. (B) Rea
cells. OVSAHO cells were seeded in ACEA’s 96X e-plate™ at a density of 15 
indicates the time of the addition of DMBO. Data represent the mean values ±
Inhibition of DMBO against the proliferation of SKOV-3 cells. SKOV-3 cells
concentrations of DMBO (1, 17 or 195 lM) or mifepristone (155 lM). The total nu
the proliferation of SKOV-3 cells was presented.3.2. Examination of the binding of DMBO to growth factors and chemokines
In recent years, many high-throughput methodologies have been
developed to identify potential anti-cancer molecules [28]. In view of
the fact that, the synthesized compounds appeared to mimic the pyrano-
side ring structure of HS; we expected that these compounds should have
binding ability with heparin-binding growth factors and they must dis-
play some characteristics common to those of some well known HS mi-
metic molecules. We conducted a novel SPR assay to screen the ability
of small molecules (around 69 molecules) to bind various growth fac-
tors/cytokines such as VEGF, HB-EGF, and TNF-a which are thought toing of the effects of DMBO on the proliferation of LM8G7 cells. LM8G7 cells
ntinuously monitored using the RT-CES system up to 24 h, at which point
l-time monitoring of the effects of DMBO on the proliferation of OVSAHO
103 cells per well and DMBO was added as described above. The arrow
S.D. for three identical wells from three independent experiments. (C) %
were cultured overnight and incubated with or without the indicated
mber of viable cells was determined and the % inhibition of DMBO against
Basappa et al. / Cancer Letters 297 (2010) 231–243 237be involved in the progression of cancer. Recently we improved our
photo-afﬁnity SPR imaging technique by reviewing the thiol linkers used
to coat the surface of the gold substrate [35]. A new photo-afﬁnity linker
(Supplemental Fig. 1) improved the sensitivity with which the interaction
between small molecules and proteins was detected, and allowed the
detection of the direct binding of growth factors/cytokines to small mol-
ecules. An overview of the SPR analysis is shown in Fig. 2A. DMBO and
other screened small molecules were immobilized on the photo-afﬁn-
ity-linker-coated gold substrates. In our in vitro experimental conditions,
strong to moderate SPR signals for the direct binding of DMBO with VEGF,
TNF-a and HB-EGF were found (Fig. 2B–D and Supplemental Figs. 2–4).
We demonstrated here that DMBO interacted signiﬁcantly with VEGF,
TNF-a, and HB-EGF directly as detected by SPR assay, when compared to
other compounds synthesized (Supplemental Scheme 1). The SPR signal
of DMBO was signiﬁcantly stronger than that of other structurally similar
compounds having the same oxazine nucleus (Fig. 2B–D). We compared
the binding speciﬁcity of DMBO to the growth factors/cytokines with
the similar scaffold molecule, which bearing different substitution at
the second position of the oxazine nucleus. The compounds like
4a,5,6,7,8,8a-hexahydro-4a-(4-methoxyphenyl)-4H-benzo[e][1,3]oxazine
(MBO); 2-(4-ﬂuorophenyl)-4a,5,6,7,8,8a-hexahydro-4a-(4-methoxy-
phenyl)-4H-benzo[e][1,3]oxazine (FMBO); 2-(4-chlorophenyl)-
4a,5,6,7,8,8a-hexahydro-4a-(4-methoxyphenyl)-4H-benzo[e][1,3]oxazine
(CMBO) and 2-(3-Pyridyl)-4a,5,6,7,8,8a-hexahydro-4a-(4-methoxy-
phenyl)-4H-benzo[e][1,3] oxazine (PMBO) were interacted with the
growth factors/cytokines weakly when compared to DMBO (Fig. 2B–D).Fig. 4. Effects of DMBO against the metastatic potential of mouse osteosarcoma c
in 200 lL of DMEM via the tail. Some mice received an intravenous injection of
4 weeks, the mice were sacriﬁced, the number of liver nodules was counted macr
injected animals. Representative livers from mice injected with LM8G7 cells treat
average liver weight of the control and the DMBO treated mice (C). Heparin fro
synergistic or additive effects of DMBO and heparin were investigated by sub
(2.5 mg/kg body weight) or DMBO (0.5 mg/kg body weight) and heparin (5.0 mg/
three independent experiments and each experiment was conducted with six mThis indicates that the 2,6-diﬂuorophenyl group of DMBO is important
for the strong interaction with VEGF, TNF-a, and HB-EGF and very weakly
with FGF-2 (Supplemental Fig. 5). DMBO did not bind to other heparin-
binding growth factors such as pleiotrophin and midkine (Supplemental
Figs. 6 and 7). These results indicate that the compound DMBO binds
more speciﬁcally towards VEGF and led us to speculate that DMBO may
be used to modulate the VEGF-mediated cellular pathways. However,
the molecular mechanism of DMBO binding with these growth factors
is unknown at this point. In addition, DMBO interacted with BSA (Supple-
mental Fig. 8) when compared to other structurally similar molecules,
encourages the development of BSA–DMBO composite drug carrier sys-
tems for cancer therapeutic studies like many anti-cancer drugs in the
near future. It has been shown that albumin plays an increasing role as
a drug carrier in vivo to a great number of therapeutic drugs such as pen-
icillins, sulfonamides, and indole compounds [36].
3.3. Effects of DMBO on the proliferation of growth factors secreting cancer
cells
Arrest of tumor cell proliferation in the target organ is the ultimate
objective of anti-cancer therapy [37]. To validate the direct binding ability
of DMBO with the growth factors/cytokines and to know the biological
effects, we investigated the anti-proliferative effect of DMBO on tumor
cells, which are known to secrete the growth factors/cytokines endoge-
nously. Initially, we examined the effect of DMBO on the proliferation of
LM8G7 cells. DMBO (10–80 lM) inhibited the proliferation ofells. C3H/HeN mice were intravenously injected with 1  106 LM8G7 cells
DMBO (0.25, 0.5, 1.0 or 1.5 mg/kg body weight) on day 3, 5 and 10. After
oscopically, and the liver weight was measured in the control and DMBO-
ed with DMEM (A) and DMBO (0.5 mg/kg body weight) (B) are shown. The
m porcine intestinal mucosa was used as a positive control. The possible
sequent administration of DMBO (0.25 mg/kg body weight) and heparin
kg body weight) as described above. Data represent mean values ± S.D. for
ice per group. P < 0.05 versus control. Mann–Whitney U test.
238 Basappa et al. / Cancer Letters 297 (2010) 231–243VEGF-expressing LM8G7 cells dose-dependently (Fig. 3A) with an IC50 va-
lue of 13 lM. Further, DMBO also inhibited the proliferation of TNF-a-
expressing OVSAHO cells (Fig. 3B) with an IC50 value of 16 lM. In addition,
DMBO at 195 lM completely inhibited (99%) the proliferation of HB-EGF
expressing SKOV-3 cells, whereas mifepristone, a positive control, at
155 lM had a lesser effect (63%) (Fig. 3C). The compounds like MBO,
FMBO, CMBO, or PMBO inhibited the proliferation of tumor cells to a lesser
extent, when compared to DMBO (Supplemental Table 1). Interestingly,
DMBO did not induce apoptosis on these cells (data not shown).
3.4. DMBO prevents liver metastasis in vivo
Inhibition of metastasis represents an attractive approach to the
treatment of highly malignant tumors [38]. Mice given an intravenous
injection of LM8G7 cells developed copious metastatic nodules in theFig. 5. Inhibitory effects of DMBO against the catalytic activity of heparanase
degradation of the FITC-HS substrate, using gel ﬁltration HPLC degradation of FITC
[26] with excitation and emission wavelengths of 490 and 520 nm respectively.
decrease in the forward half area of FITC-HS following suramin treatment (PC),
calculated. (B) Overall inhibition rates of DMBO (28, 58, 78, 100 or 118 lM) on he
HS remaining after the incubation of LM8G7 cell lysates in the presence or absenc
the indicated concentration (55, 104 or 206 lM). Using the cell lysates, the
contained the substrate but no cell lysate. PC I and PC II, positive controls I and
P < 0.05 versus control. P < 0.01 versus control. Mann–Whitney U test.liver within 30 days (Fig. 4A). In our dose ﬁxation study, to elucidate
the effective dose of DMBO or heparin, we used several concentration
of DMBO (0.25, 0.5, 1.0 or 1.5 mg/kg body weight) alone or heparin (2.5
or 5.0 mg/kg body weight) alone. Our in vivo study revealed that DMBO
at the concentration of 0.25 mg/kg body weight and heparin 2.5 mg/kg
body weight had no anti-tumor effect. In contrast, mice treated intrave-
nously with DMBO at 0.5, 1.0 or 1.5 mg/kg body weight were completely
free of metastatic nodules in the liver (Fig. 4B). Moreover, we did not note
any signiﬁcant advantage provided by the 1.0 and 1.5 mg/kg body weight
dose over the 0.5 mg/kg body weight dose, hence the minimal effective
dose of DMBO was considered to be 0.5 mg/kg body weight.
Measurements of liver weight, which reﬂects tumor burden, gave
similar results, with DMBO almost completely suppressing the increase
in liver weight by inhibiting the formation of tumor nodules (Fig. 4C).
The animals tolerated the dosages of DMBO well, showing no signs of tox-. (A) The inhibitory action of DMBO (100 lM) on heparanase-mediated
-HS were monitored by the ﬂuorescence intensity as described previously
When compared to negative control (NC, the uninhibited heparanase), the
and the inhibition of heparanase activity by DMBO (100 lM DMBO) was
paranase activity in the cell-free system. (C) Mean absorbance of the intact
e of DMBO is shown. The adhered LM8G7 cells were treated with DMBO at
heparan-degrading activity was determined. The negative control (NC)
II. Data represent mean values ± S.D. for three independent experiments.
Fig. 6. Effects of DMBO against the migration and invasion of LM8G7 cells. LM8G7 cells were plated on BD BioCoat™ chambers (BD Biosciences) in the
presence of fetal bovine serum. The cell migration (without Matrigel coat) and invasion (with Matrigel coat) were measured as described under
‘‘Experimental Procedures.” Effects of DMBO (0.5–5 lM) or heparin (100 lg/mL) on the migration (A) and invasion (B) of LM8G7 cells measured as
described under ‘‘Experimental Procedures.” The data represent the mean value ± S.D. for two independent experiments. P < 0.05 versus control, P 0.01
versus control, Mann–Whitney U test.
Fig. 7. Effect of DMBO on the migration of UV$2 cells. The cell monolayers were wounded by scratching, incubated with DMSO (control) or with DMBO (0.5
or 1 lM) in the presence of exogenous VEGF (2 ng/mL) and the wound healing process were photographed digitally with an inverted microscope at 0 h and
8 h.
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240 Basappa et al. / Cancer Letters 297 (2010) 231–243icity or weight loss during the experiments. To gain further insight into
the toxic effects of DMBO (1.5 mg/kg body weight), histological analysis
was performed using hematoxylin and eosin (H and E) staining of liver
and kidney of both normal and DMBO treated mice. The histological eval-
uation showed no apparent abnormalities in any DMBO treated mice
(Supplemental Fig. 9). Moreover, DMBO failed to show any anti-coagulant
activity in vitro (data not shown). Heparin (5.0 mg/kg body weight) from
porcine intestinal mucosa, a positive control also prevented the increase
in liver weight (Fig. 4C) by suppressing the formation of metastatic nod-
ules in the liver.
Further to understand whether DMBO and heparin has synergistic or
additive effects, we used the combination of DMBO (0.25 mg/kg body
weight) and heparin (2.5 mg/kg body weight) or DMBO (0.5 mg/kg body
weight) and heparin (5.0 mg/kg body weight). In LM8G7 cells injected
mice, monotherapy with DMBO (0.25 mg/kg body weight) or heparin
(2.5 mg/kg body weight) failed to inhibit tumor growth, while combina-
tion of DMBO and heparin at the same dosage dramatically enhanced
the anti-tumor activity compared with single-agent treatments
(Fig. 4C). Treatment of mice with a higher dose of either DMBO
(0.5 mg/kg body weight) or heparin (5 mg/kg body weight) alone was
able to elicit the same response as compared to the combination of both
at the same dosage, suggesting that a synergistic inhibition of tumor
growth is evident only at the combined low dose of DMBO (0.25 mg/kg
body weight) and heparin (2.5 mg/kg body weight).
3.5. DMBO inhibits human heparanase enzymatic activity in a cell-free
system
The heparanase is known to degrade the HS chains speciﬁcally [39].
Using FITC-labelled HS as a substrate, we evaluated the ability of DMBO
to inhibit heparanase-mediated degradation of HS in a gel-permeation
chromatography. The resulting chromatogram revealed that DMBOFig. 8. Effects of DMBO on the tube formation of UV$2 cells. UV$2 cells were
network of intact tubes in 8 h on ECMatrix™ (control). After treatment wit
(magniﬁcation 20) in 8 h on ECMatrix™. (D) Inhibition rates of DMBO on the tub
randomly chosen regions and expressed as the percentage of the control, and t
versus control. Mann–Whitney U test.signiﬁcantly inhibited the enzymatic activity of human heparanase
(Fig. 5A). DMBO strongly and concentration dependently inhibited the
heparanase activity with an IC50 value of 65 lM (Fig. 5B). In order to know
the speciﬁcity of DMBO, we also studied the effects of DMBO on hyaluron-
idase catalytic activity in vitro (see Supplemental Experimental Proce-
dures for details). Supplemental Fig. 10 shows the chromatograms of
FITC-labelled hyaluronic acid (HA) digested by the hyaluronidase in the
presence or absence of DMBO. The enzyme activity of hyaluronidase
was not inhibited by the DMBO, indicates that DMBO is not an inhibitor
of hyaluronidase. In addition, we also evaluated the effect of DMBO on
chondroitinase (CSase) ABC catalytic activity by digesting chondrotin
sulfate (CS)-A in the presence or absence of DMBO (see Supplemental
Experimental Procedures for details). CSase ABC, digested the CS-A even
in the presence of DMBO (Supplemental Fig. 11). These results indicate
the speciﬁcity of DMBO towards the heparanase.3.6. Effects of DMBO on the heparan-degrading activity of LM8G7 cells
During metastasis, the activation of a multitude of enzymes/proteins
usually occurs. For example, the active secretion of heparanase by tumor
cells has been reported [10]. Hence, we determined the effects of DMBO
on the heparan-degrading activity of LM8G7 cells. A high level of hepa-
ran-degrading activity was detected in LM8G7 cells. The control cell
lysates without DMSO (positive control I) or with DMSO (positive control
II) degraded the intact HS effectively (Fig. 5C). DMBO at 104 and 206 lM
signiﬁcantly inhibited the degradation of intact HS by 63% and 85%
respectively, but DMBO at 55 lM failed to inhibit the heparan-degrading
activity (Fig. 5C). Thus, DMBO at higher concentrations signiﬁcantly abol-
ished the heparan-degrading activity of LM8G7 cells. Therefore, DMBO
may prevent the degradation of cell-surface and extracellular HS by hep-
aranase, thereby preventing cancer metastasis.seeded in ECMatrix™-coated 96-well plates; (A) UV$2 cells formed the
h 0.5 lM (B), 1.0 lM (C), the tube structures were severely disrupted
e formation of UV$2 cells. The number of intact tubes were counted in ﬁve
he results are expressed as mean ± S.D. P < 0.05 versus control. P < 0.01
Fig. 9. Effects of DMBO on the proliferation of UV$2 in the presence or
absence of VEGF. (A) UV$2 cells were cultured overnight and incubated
with the indicated concentrations of DMBO (1–59 lM) or heparin
(100 lg/mL) in the presence of exogenous VEGF (2 ng/mL) for 48 h. The
total number of viable cells was determined and the % inhibition of DMBO
against the VEGF-induced proliferation of UV$2 cells is presented. (B) %
Inhibition of DMBO against the proliferation of UV$2 cells in the absence
of VEGF. UV$2 cells were cultured overnight and incubated with the
indicated concentrations of DMBO (2–96 lM) or cisplatin (10 lM). The
total number of viable cells was determined and the % inhibition of DMBO
against the proliferation of UV$2 cells was presented. Data represent the
mean values ± S.D. for four identical wells from three independent
experiments. P < 0.05 versus control. P < 0.01 versus control. Mann–
Whitney U test.
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expressing VEGF and heparanase
Heparanase expression has been consistently correlated with the
metastatic potential of tumor cells. Here, we used the Transwell migra-
tion assay to evaluate the effects of DMBO on migration and in vivo inva-
sion assay for invasion of LM8G7 cells that stably expresses VEGF and
heparanase (Fig. 6A and B). As shown in Fig. 6A and B, the LM8G7 cells
abundantly migrated through the ﬁlter (without Matrigel coat) or
invaded through Matrigel coat (basement membrane material) and
passed through the pores to reach the underside of the ﬁlter membrane
following stimulation with 10% FBS. DMBO at 0.5–5 lM concentrations
markedly suppressed the migration and invasion of LM8G7 cells dose-
dependently (Fig. 6A and B). These data suggest that the DMBO may inhi-
bit the metastasis of LM8G7 cells to the liver, in part by affecting the
migration and invasion of cancer cells.
3.8. DMBO is anti-angiogenic in vitro
Angiogenesis is believed to be mediated by migration, differentiation
(tube formation) and proliferation of endothelial cells. Since tumor growth
is dependent onangiogenesis, targeting the tumorvasculaturemakes sense
as an anti-tumor strategy [40]. We examined whether DMBO can inhibit
VEGF-mediated in vitro migration and differentiation of endothelial cells
by performing in vitromigration and tube formation assays on ECMatrix™
respectively. DMBO selectively inhibited themigration (Fig. 7A–D) and for-
mation of vascular tubes on ECMatrix™ in a dose-dependent manner
(Fig. 8A–D). With regard to control, DMBO showed a remarkable suppres-
sion of migration and vascular tubes formation, with inhibition rates of
26% and 54% in migration and 52% and 81% in tube formation at 0.5 and
1 lM concentration respectively. Thus DMBO blocked the VEGF-induced
migration and tube formation of UV$2 cells. Interestingly, DMBO does
not inhibit FGF-2 induced angiogenesis ofUV$2 cells (datanot shown). This
observation correlates with our SPR analysis that DMBO showed a weak or
no interaction with FGF-2 (Supplementary Fig. 5).
3.9. Effect of DMBO on UV$2 cells proliferation
The proliferation of endothelial cells to form microvessels is critical
for angiogenesis. In fact, inhibition of angiogenic factors mediated prolif-
eration of endothelial cells would be an effective anti-angiogenic therapy
and ultimately for cancer prevention. Hence, we tested the effect of
DMBO on the VEGF-induced proliferation of endothelial (UV$2) cells.
Markedly, the compound DMBO, strongly bound with VEGF signiﬁcantly
inhibited the VEGF-induced proliferation of UV$2 cells by 27%, 64%, and
94% at 14, 28 and 59 lM respectively (Fig. 9A). Notably, results shows
that compound DMBO suppressed the proliferation of endothelial cells,
but the concentration of DMBO and time required to suppress cell prolif-
eration was high compared with that required to suppress the cell migra-
tion and tube formation (0.5 and 1 lM). Hence, the inhibitory effect of
DMBO on the migration and tube formation could not be attributed to
the anti-proliferative activity. Taken together, we demonstrated that
DMBO can block the VEGF-mediated angiogenic response on endothelial
cells probably by reducing the afﬁnity of VEGF for its receptors on endo-
thelial cells or associated with a signiﬁcant loss in bioactivity. Further
more, the cytotoxic effects of DMBO (2–96 lM) was tested on UV$2 in
the absence of VEGF. Interestingly, after a longer incubation (72 h) of
DMBO, in the absence of exogenous VEGF, very less cytotoxicity (Fig
9B) was observed even at higher concentration (96 lM) when compared
to cisplatin (10 lM). Taken together, these results show that the anti-pro-
liferative effect of DMBO depends not only on the concentration, but also
on the condition of the pathological settings.
3.10. Effects of DMBO or heparin on the proliferation of LM8G7 cells
Numerous studies have shown that overexpression of VEGF, a hepa-
rin-binding growth factor, and its receptor plays an important role in tu-
mor-associated angiogenesis and subsequent growth and metastasis [41].
Many sugar-based derivatives have been reported as strong inhibitors of
tumor progression and metastasis. However, evidence for the direct bind-
ing of small molecules to VEGF is still lacking. Our SPR analysis demon-
strated that DMBO directly bound to VEGF probably via non-covalent
interactions (Fig. 2B). Further, to support the hypothesis that DMBOmay also act through growth factor mediated cell signalling, we analyzed
the effects of DMBO or heparin on the proliferation of LM8G7 cells in the
presence of various concentration of exogenous VEGF. As expected, addi-
tion of exogenous VEGF seems to promote the proliferation of LM8G7
cells to some extend in an autocrine manner. Presence of excess exoge-
nous VEGF partially counteracted the anti-proliferative effects of DMBO
on the LM8G7 cells (Fig. 10A). These observations suggest that DMBO
may bind with VEGF and thereby inhibit the mitogenic effects of VEGF
on the proliferation of LM8G7 cells, but the exact mechanism is still not
obvious. Further, the synergistic effect of DMBO and heparin on the pro-
liferation of LM8G7 cells was studied by using DMBO (25 or 50 lM) alone
and heparin (25 or 50 lg/mL) alone or in combination of DMBO (25 or
50 lM) with heparin (25 or 50 lg/mL). The proliferation of LM8G7 cells
was strongly inhibited in combination of both DMBO and heparin.
(Fig. 10B). Our data have provided evidence that a synergistic anti-prolif-
erative effect was observed when DMBO combined with heparin and
these results are consistent with the in vivo anti-tumor effect.4. Conclusion
Althoughwe have synthesizedmany oxazine derivatives
thatbear thesamenucleusas thatofDMBO, to thebestof our
knowledge, this is the ﬁrst report on a synthetic oxazine that
appears to mimic functional groups and pyranosidic ring
Fig. 10. Effects of DMBO and heparin on the proliferation LM8G7 cells. (A) LM8G7 cells were cultured overnight and incubated with DMBO (50 lM) or
heparin (100 lg/mL) in the presence of various concentrations of VEGF (2–6 ng/mL) for 48 h. The total number of viable cells was determined and the %
inhibition of DMBO (50 lM) or heparin (100 lg/mL) against the VEGF-induced proliferation of LM8G7 cells is presented. (B) Synergistic anti-proliferative
effect of DMBOwith heparin on LM8G7 cells. LM8G7 cells were cultured overnight and incubated with DMBO (25 or 50 lM) alone and heparin (25 or 50 lg/
mL) alone or in combination of DMBO (25 or 50 lM) with heparin (25 or 50 lg/mL) for 48 h. The total number of viable cells was determined and the %
inhibition of DMBO or the synergistic effect of DMBO and heparin against the proliferation of LM8G7 cells is presented. Data represent the mean
values ± S.D. for four identical wells from three independent experiments. P < 0.05 versus control. P < 0.01 versus control. Mann–Whitney U test.
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kines with high afﬁnity. Thus, we propose that DMBO binds
VEGF andmight effectively block the ability of VEGF to acti-
vate its receptor and its further signalling. Further, the
in vivo anti-metastaticmechanism of DMBOon LM8G7 cells
lies greatly in its ability to interrupt heparanase-associated
pathologic events and this effect ismost important andcom-
parable to other sugar mimetic anti-metastatic agents [42].
In addition, DMBO inhibited the catalytic activity of hep-
aranase. Also, DMBO may block the VEGF-mediated angio-
genic responses in vitro on endothelial cells. Thus, DMBO
anti-tumor activity could be attributed at least in part, by
modulating the early and late steps of metastasis involving
tumor and endothelial cell functions. Evidently, DMBO
showed an anti-tumor effect with heparin synergistically
in osteosarcoma model. However, additional studies are
needed to elucidate the detailed mechanism of action of
DMBO to develop new carbohydrate-mimetic-based cancer
therapeutic molecules.
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